|
GB587992A
(en)
|
1944-12-11 |
1947-05-12 |
Charles William Scaife |
Improvements in and relating to the production of organic nitrogen compounds
|
|
US3578687A
(en)
|
1968-01-30 |
1971-05-11 |
Texaco Inc |
Process for producing 4-nitroalkanoic acids
|
|
US3819561A
(en)
|
1970-10-23 |
1974-06-25 |
Aerojet General Co |
Wetting agents for non-aqueous dispersions
|
|
JPS5313608B2
(https=)
|
1972-06-16 |
1978-05-11 |
|
|
|
JPS5318013B2
(https=)
|
1973-03-19 |
1978-06-13 |
|
|
|
US4599430A
(en)
|
1981-12-21 |
1986-07-08 |
The Standard Oil Company |
Nitrogenation of hydrocarbons, including the production of maleimide
|
|
JPS62132804A
(ja)
|
1985-12-05 |
1987-06-16 |
Aguro Kanesho Kk |
植物生長調節剤
|
|
US5412137A
(en)
|
1993-06-07 |
1995-05-02 |
Sandoz Ltd. |
Process for preparing phosphinyloxy propanaminium inner salt derivatives
|
|
IL114852A
(en)
|
1994-08-08 |
2000-02-29 |
Debiopharm Sa |
Pharmaceutically stable preparation of oxaliplatinum
|
|
DE69524639T2
(de)
|
1994-10-13 |
2002-08-08 |
Peptech Ltd., North Ryde |
Modifizierte mehrfach ungesättigte fettsäuren
|
|
US5919816A
(en)
|
1994-11-14 |
1999-07-06 |
Bionumerik Pharmaceuticals, Inc. |
Formulations and methods of reducing toxicity of antineoplastic agents
|
|
US5741211A
(en)
|
1995-10-26 |
1998-04-21 |
Medtronic, Inc. |
System and method for continuous monitoring of diabetes-related blood constituents
|
|
GB9618420D0
(en)
|
1996-09-04 |
1996-10-16 |
Scotia Holdings Plc |
Fatty acid treatment
|
|
US6187747B1
(en)
|
1997-09-08 |
2001-02-13 |
Panacea Biotech Limited |
Pharmaceutical composition comprising cyclosporin
|
|
GB9722520D0
(en)
|
1997-10-24 |
1997-12-24 |
Pfizer Ltd |
Compounds
|
|
KR100569319B1
(ko)
|
1997-10-30 |
2006-04-07 |
모리시타 진탄 가부시키가이샤 |
불포화 지방산 또는 이들의 유도체를 내용물로 하는 캡슐제제 및 그의 제조방법
|
|
US6362178B1
(en)
|
1997-11-12 |
2002-03-26 |
Bayer Aktiengesellschaft |
2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
|
|
US7795246B2
(en)
|
1998-08-06 |
2010-09-14 |
Cephalon, Inc. |
Particle-forming compositions containing fused pyrrolocarbazoles
|
|
WO2000009075A2
(en)
|
1998-08-14 |
2000-02-24 |
Galenica Pharmaceuticals, Inc. |
Chemically modified saponins and the use thereof as adjuvants
|
|
CZ20012627A3
(cs)
|
1999-01-20 |
2002-01-16 |
Arzneimittelwerk Dresden Gmbh |
Pouľití imidazo [1,5-a] pyrido [3,2-e]pyrazinonů jako léčiva
|
|
MXPA01009893A
(es)
|
1999-04-01 |
2003-07-28 |
Esperion Therapeutics Inc |
Compuestos con eter, composiciones y usos de estos.
|
|
AU5319499A
(en)
|
1999-07-22 |
2001-02-13 |
Ivan L. Cameron |
Fatty acids to minimize cancer therapy side effects
|
|
SE9903028D0
(sv)
|
1999-08-27 |
1999-08-27 |
Astra Ab |
New use
|
|
AUPQ291499A0
(en)
|
1999-09-17 |
1999-10-07 |
Women's And Children's Hospital Adelaide |
Novel nitro and sulphur containing compounds
|
|
US6346231B1
(en)
|
1999-10-06 |
2002-02-12 |
Joar Opheim |
Flavored gelatin capsule and method of manufacture
|
|
IL139457A0
(en)
|
1999-11-08 |
2001-11-25 |
Pfizer |
Compounds for the treatment of female sexual dysfunction
|
|
US20010037598A1
(en)
|
1999-12-14 |
2001-11-08 |
Suppes Galen J. |
Process for producing cetane improvers from triglycerides
|
|
JP4932116B2
(ja)
|
2000-02-16 |
2012-05-16 |
ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド |
アスピリン誘発脂質メディエータ
|
|
AR030416A1
(es)
|
2000-04-13 |
2003-08-20 |
Pharmacia Corp |
COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA
|
|
AR032318A1
(es)
|
2000-04-13 |
2003-11-05 |
Pharmacia Corp |
Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
|
|
AR034120A1
(es)
|
2000-04-13 |
2004-02-04 |
Pharmacia Corp |
Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
|
|
US20040006248A1
(en)
|
2000-06-28 |
2004-01-08 |
Zambon Group S.P.A |
Process for the preparation of nitroalkenes
|
|
AR031129A1
(es)
|
2000-09-15 |
2003-09-10 |
Pharmacia Corp |
Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
|
|
DE60220766T2
(de)
|
2001-03-02 |
2008-03-06 |
Debiopharm S.A. |
Verwendung eines eine oxaliplatinlösung beinhaltenden fläschchens
|
|
IL158322A0
(en)
|
2001-04-18 |
2004-05-12 |
Prometic Biosciences Inc |
Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
|
|
US7105556B2
(en)
|
2001-05-30 |
2006-09-12 |
Bristol-Myers Squibb Company |
Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
|
|
JPWO2002102364A1
(ja)
|
2001-06-18 |
2004-09-30 |
山田 幸子 |
ＰＰＡＲγ作動性医薬組成物
|
|
US6998395B2
(en)
|
2001-08-17 |
2006-02-14 |
University Of Pittsburg, |
Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders
|
|
GB0123961D0
(en)
|
2001-10-05 |
2001-11-28 |
Astrazeneca Ab |
Process and intermediates
|
|
HN2002000317A
(es)
|
2001-11-02 |
2003-05-21 |
Pfizer |
Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
|
|
EP1444009A1
(en)
|
2001-11-02 |
2004-08-11 |
Pfizer Products Inc. |
Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
|
|
JP4652685B2
(ja)
|
2001-11-06 |
2011-03-16 |
ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド |
喘息および炎症性気道疾患の治療におけるリポキシンおよびアスピリン誘発リポキシンおよびそれらの安定な類似物
|
|
GB2388111A
(en)
|
2002-05-01 |
2003-11-05 |
Bayer Ag |
Novel imidazotriazinone compounds
|
|
US6684626B1
(en)
|
2002-07-30 |
2004-02-03 |
General Electric Company |
Aircraft gas turbine engine with control vanes for counter rotating low pressure turbines
|
|
US7759395B2
(en)
|
2002-08-12 |
2010-07-20 |
The Brigham And Women's Hospital, Inc. |
Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
|
|
US20060100278A1
(en)
|
2002-08-20 |
2006-05-11 |
Cooper Garth J S |
Dosage forms and related therapies
|
|
EP2384750A1
(en)
|
2002-09-27 |
2011-11-09 |
Martek Biosciences Corporation |
Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid
|
|
AU2003284885A1
(en)
|
2002-10-21 |
2004-05-13 |
Kensey Nash Corporation |
Device and methods for sequential, regional delivery of multiple cytotoxic agents
|
|
US7166575B2
(en)
|
2002-12-17 |
2007-01-23 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
|
|
US20040220186A1
(en)
|
2003-04-30 |
2004-11-04 |
Pfizer Inc. |
PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
|
|
WO2005016864A1
(en)
|
2003-07-29 |
2005-02-24 |
The Arizona Disease Control Research Commission |
Conjugated nitro alkene anticancer agents based on isoprenoid metabolism
|
|
US20050136103A1
(en)
|
2003-09-17 |
2005-06-23 |
Ben-Sasson Shmuel A. |
Compositions capable of facilitating penetration across a biological barrier
|
|
US7935365B2
(en)
|
2003-10-22 |
2011-05-03 |
Enzymotec, Ltd. |
Glycerophospholipids for the improvement of cognitive functions
|
|
WO2005041972A1
(en)
|
2003-10-31 |
2005-05-12 |
Pfizer Products Inc. |
Phosphodiesterase 9 inhibition as treatment for obesity-related conditions
|
|
CA2554735A1
(en)
|
2004-01-30 |
2005-08-11 |
Peplin Biolipids Pty Ltd |
Therapeutic and carrier molecules
|
|
US8241670B2
(en)
|
2004-04-15 |
2012-08-14 |
Chiasma Inc. |
Compositions capable of facilitating penetration across a biological barrier
|
|
US7776916B2
(en)
|
2004-04-28 |
2010-08-17 |
The Uab Research Foundation |
Nitrated lipids and methods of making and using thereof
|
|
BRPI0513508B1
(pt)
|
2004-07-19 |
2021-06-01 |
Biocon Limited |
Conjugados de insulina-oligômero, formulações e usos desses
|
|
TW200613306A
(en)
|
2004-07-20 |
2006-05-01 |
Osi Pharm Inc |
Imidazotriazines as protein kinase inhibitors
|
|
EP1772149A1
(en)
|
2004-07-27 |
2007-04-11 |
Kowa Company. Ltd. |
Drug for prevention or treatment of diabetes
|
|
WO2006055965A2
(en)
|
2004-11-19 |
2006-05-26 |
Martek Biosciences Corporation |
Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
|
|
EP1817009A2
(en)
|
2004-11-24 |
2007-08-15 |
Spi Pharma, Inc. |
Orally disintegrating compositions
|
|
AU2011202664B2
(en)
|
2004-12-08 |
2012-04-05 |
Cedars-Sinai Medical Center |
Methods for diagnosis and treatment of Crohn's disease
|
|
US20070032420A1
(en)
|
2005-02-09 |
2007-02-08 |
Entelos, Inc. |
Treating diabetes with glucagon-like peptide-1 secretagogues
|
|
US7709468B2
(en)
|
2005-09-02 |
2010-05-04 |
Abbott Laboratories |
Imidazo based heterocycles
|
|
GB0522569D0
(en)
|
2005-11-04 |
2005-12-14 |
Univ Bath |
Biocompatible drug delivery device
|
|
TW200815436A
(en)
|
2006-05-30 |
2008-04-01 |
Elbion Ag |
4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
|
|
US9274129B2
(en)
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Methods and reagents for detecting bioactive lipids
|
|
WO2008008767A2
(en)
|
2006-07-14 |
2008-01-17 |
Cedars-Sinai Medical Center |
Methods of using ppar-gamma agonists and caspase-dependent chemotherapeutic agents for the treatment of cancer
|
|
JP2009545527A
(ja)
|
2006-07-19 |
2009-12-24 |
リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド |
粘膜炎の治療用の組成物及び方法
|
|
WO2008029589A1
(en)
|
2006-09-08 |
2008-03-13 |
Tokuyama Corporation |
Method and equipment for producing group-iii nitride
|
|
CA2671980C
(en)
|
2006-12-13 |
2015-05-05 |
Aska Pharmaceutical Co., Ltd. |
Quinoxaline derivatives
|
|
WO2008072778A1
(ja)
|
2006-12-13 |
2008-06-19 |
Aska Pharmaceutical Co., Ltd. |
尿路系疾患の処置剤
|
|
EP2120920A4
(en)
|
2007-02-20 |
2011-06-15 |
Martek Biosciences Corp |
OXYLIPINES OF LONG-CHAIN MULTIPLE-UNSATURATED FATTY ACIDS AND METHOD FOR THEIR PREPARATION AND USE
|
|
PT2152712E
(pt)
|
2007-05-11 |
2012-02-29 |
Pfizer |
Compostos amino-heterocíclicos
|
|
DE102007032349A1
(de)
|
2007-07-11 |
2009-01-15 |
Bayer Healthcare Ag |
Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
|
|
EP2679224A1
(en)
|
2007-08-01 |
2014-01-01 |
University of Pittsburgh of the Commonwealth System of Higher Education |
Nitro oleic acid modulation of type II diabetes
|
|
CA2699483A1
(en)
|
2007-09-14 |
2009-03-26 |
Resolvyx Pharmaceuticals, Inc. |
Compositions and methods for modulating immune function
|
|
JP2011513202A
(ja)
|
2008-03-10 |
2011-04-28 |
武田薬品工業株式会社 |
ベンズイミダゾール化合物の結晶
|
|
EP2271929B1
(en)
|
2008-04-18 |
2015-11-25 |
The University of Utah Research Foundation |
Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions
|
|
CN102083787A
(zh)
|
2008-05-01 |
2011-06-01 |
康普雷克萨公司 |
乙烯基取代的脂肪酸
|
|
WO2009149496A1
(en)
|
2008-06-10 |
2009-12-17 |
Central Northern Adelaide Health Service |
Treatment of diabetes and complications thereof and related disorders
|
|
US20140024713A1
(en)
|
2008-06-19 |
2014-01-23 |
University Of Utah Research Foundation |
Use of nitrated lipids for treatment of side effects of toxic medical therapies
|
|
WO2009155439A2
(en)
|
2008-06-19 |
2009-12-23 |
University Of Utah Research Foundation |
Use of nitrated lipids for treatment of side effects of toxic medical therapies
|
|
EP2320903B1
(en)
|
2008-07-29 |
2017-01-18 |
Nerviano Medical Sciences S.r.l. |
THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT
|
|
CN104119242B
(zh)
|
2008-10-09 |
2017-07-07 |
泰米拉制药公司 |
改善的氨基脂质和递送核酸的方法
|
|
JP2012513774A
(ja)
|
2008-12-31 |
2012-06-21 |
ニトロメガ コーポレーション |
ニトロ脂肪酸を含有する栄養補助物
|
|
US8937194B2
(en)
|
2008-12-31 |
2015-01-20 |
Nitromega Corp. |
Topical compositions containing nitro fatty acids
|
|
TWI404721B
(zh)
|
2009-01-26 |
2013-08-11 |
Pfizer |
胺基－雜環化合物
|
|
US20100286271A1
(en)
|
2009-05-08 |
2010-11-11 |
Perricone Nicholas V |
Nitro-alkyl Compound Compositions
|
|
US20100286257A1
(en)
|
2009-05-08 |
2010-11-11 |
Perricone Nicholas V |
Methods Of Use Of Nitroalkane Compositions In Dermatologic Applications To Prevent or Treat Skin Aging
|
|
US20100286272A1
(en)
|
2009-05-08 |
2010-11-11 |
Perricone Nicholas V |
Methods Of Use Of Nitroalkene Compositions In Dermatologic Applications
|
|
US20110082147A1
(en)
|
2009-07-24 |
2011-04-07 |
Concert Pharmaceuticals, Inc. |
Substituted imidazotriazines
|
|
US20120136057A1
(en)
|
2009-07-29 |
2012-05-31 |
Phenomenome Discoveries Inc. |
Hydroxy fatty acid compounds and uses thereof for disease treatment and diagnosis
|
|
EP2459189A4
(en)
|
2009-07-31 |
2013-01-16 |
Univ Pittsburgh |
FATTY ACIDS AS ANTI-INFLAMMATORY AGENTS
|
|
WO2011028820A1
(en)
|
2009-09-02 |
2011-03-10 |
Concert Pharmaceuticals, Inc. |
Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
|
|
WO2011030351A2
(en)
|
2009-09-03 |
2011-03-17 |
Rubicon Research Private Limited |
Taste - masked pharmaceutical compositions
|
|
WO2011041639A2
(en)
|
2009-10-02 |
2011-04-07 |
Miller Raymond A |
Heteroatom containing substituted fatty acids
|
|
KR20120130078A
(ko)
|
2009-11-09 |
2012-11-28 |
메디비르 아베 |
신규한 1,3-옥사졸리딘 화합물 및 이의 레닌 억제제로서의 용도
|
|
WO2011098746A1
(en)
|
2010-02-09 |
2011-08-18 |
Pulmagen Therapeutics (Inflammation) Limited |
Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
|
|
KR20130054249A
(ko)
|
2010-03-15 |
2013-05-24 |
울리히 디에츠 |
공격적 치료 패턴의 치료, 진단 및 예방용 니트로카르복실산의 용도
|
|
US8563609B2
(en)
|
2010-05-13 |
2013-10-22 |
Nitromega Corp. |
Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline
|
|
JP2013534930A
(ja)
|
2010-06-28 |
2013-09-09 |
コンプレクサ，インコーポレイテッド |
糖尿病を治療するための多成分調剤
|
|
RU2603140C2
(ru)
|
2010-09-20 |
2016-11-20 |
Айронвуд Фармасьютикалз, Инк. |
Соединения имидазотриазинона
|
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
|
EP2744491B1
(en)
|
2011-08-19 |
2020-07-29 |
The University of Utah Research Foundation |
Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
|
|
WO2013051639A1
(ja)
|
2011-10-07 |
2013-04-11 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ピラゾロキノリン誘導体
|
|
SG11201502728WA
(en)
|
2011-10-10 |
2015-05-28 |
Lundbeck & Co As H |
Pde9i with imidazo pyrazinone backbone
|
|
US9271952B2
(en)
|
2011-10-11 |
2016-03-01 |
Complexa, Inc. |
Compositions and methods for treating nephropathy
|
|
DE102012008730A1
(de)
|
2011-12-02 |
2013-06-06 |
Dr. Budz GmbH |
Orale Zusammensetzungen mit ungesättigten C18-Fettsäuren und ihre Verwendung
|
|
BR112014018199A8
(pt)
|
2012-01-26 |
2021-03-02 |
H Lundbeck As |
inibidores da pde9 com cadeia principal imidazo triazinona, composição farmacêutica que os compreende, uso dos referidos inibidores e processo para sua preparação
|
|
JP6038184B2
(ja)
|
2012-02-01 |
2016-12-07 |
シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ |
リボヌクレオチドレダクターゼ阻害剤および使用方法
|
|
US10435367B2
(en)
|
2013-03-14 |
2019-10-08 |
City Of Hope |
Indirubin derivatives, and uses thereof
|
|
EP2809317A4
(en)
|
2012-02-03 |
2015-07-22 |
Univ Pittsburgh |
FATTY ACIDS AS ANTI-INFLAMMATORY ACTIVE SUBSTANCES
|
|
EP2828262A4
(en)
|
2012-03-19 |
2015-09-23 |
Forum Pharmaceuticals Inc |
IMIDAZOTRIAZINONVERBINDUNGEN
|
|
WO2013170069A1
(en)
|
2012-05-09 |
2013-11-14 |
Massachusetts Institute Of Technology |
Medicament, method, and drug delivery device for treatment of ovarian cancer
|
|
SG11201501424SA
(en)
|
2012-08-31 |
2015-03-30 |
Taris Biomedical Llc |
Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin
|
|
US20140271844A1
(en)
|
2013-03-15 |
2014-09-18 |
Nitromega Corp. |
Compositions containing nitro fatty acids
|
|
CA2944480C
(en)
|
2013-04-10 |
2021-05-18 |
Massachusetts Institute Of Technology |
Local drug delivery devices and methods for treating cancer
|
|
EP2994165A4
(en)
|
2013-05-10 |
2017-01-04 |
Nitromega Corp. |
Nutritional or dietary supplements containing fatty acids and nitrite
|
|
WO2014204872A2
(en)
|
2013-06-14 |
2014-12-24 |
Complexa, Inc. |
Composition and method for inhibition of pkng from mycobacterium tuberculosis
|
|
CN105744983B
(zh)
|
2013-08-12 |
2019-12-27 |
纳米医学系统公司 |
用于缓释在增溶剂中的低水溶性治疗剂的装置和方法
|
|
WO2015073527A1
(en)
|
2013-11-12 |
2015-05-21 |
Complexa, Inc. |
Nitroalkene tocopherols and analogs thereof for use in the treatment and prevention of inflammation related conditions
|
|
WO2015185499A1
(en)
|
2014-06-06 |
2015-12-10 |
H. Lundbeck A/S |
Pde9 inhibitors with 1-benzyl-2,5,6,8-tetrahydro-3-oxo-2,7-naphthyridine-4-carbonitrile backbone
|
|
WO2016161285A1
(en)
|
2015-04-02 |
2016-10-06 |
Aobiome Llc |
Production of nitro-fatty acids and nitro-hydrocarbons by ammonia oxidizing bacteria
|
|
HRP20240082T1
(hr)
*
|
2015-07-07 |
2024-03-29 |
H. Lundbeck A/S |
Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti
|
|
IL258476B2
(en)
|
2015-10-02 |
2023-04-01 |
Complexa Inc |
Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
|
|
DK3416964T3
(da)
|
2016-02-19 |
2021-02-22 |
Phoenix Molecular Designs |
6-Oxo-N-(1-(benzyl)-1H-pyrazol-4-YL)-6,7,8,9-tetrahydropyrido[3',2':4,5]pyrrolo[1,2-A]pyrazin-2-carboxamid-derivater som P90 ribosomal S6 kinase- (RSK-) hæmmere til behandling af cancer
|
|
TN2018000383A1
(en)
|
2016-07-06 |
2020-06-15 |
H Lundbeck As |
Pde9 inhibitors for treatment of peripheral diseases.
|
|
DK3630772T3
(da)
|
2017-05-26 |
2024-02-05 |
Cardurion Pharmaceuticals Inc |
Fremgangsmåder til fremstilling og anvendelse af pde9-hæmmere
|
|
FI3801526T3
(fi)
|
2018-05-25 |
2024-03-20 |
Cardurion Pharmaceuticals Inc |
6-[(3s,4s)-4-metyyli-1-(pyrimidin-2-yylimetyyli)pyrrolidin-3-yyli]-3-tetrahydropyran-4-yyli-7h-imidatso[1,5-a]pyratsin-8-onin monohydraattimuotoja ja kiteisiä muotoja
|
|
EP3843737A4
(en)
|
2018-08-31 |
2022-06-01 |
Imara Inc. |
PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE
|
|
EP3946348A4
(en)
|
2019-04-05 |
2023-08-02 |
Imara Inc. |
PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE
|
|
CN114072151A
(zh)
|
2019-05-07 |
2022-02-18 |
伊马拉公司 |
用于治疗地中海贫血的pde9抑制剂
|